摘要
目的探讨尿激酶静脉溶栓治疗急性心肌梗死(AMI)的疗效及预后。方法回顾分析本院收治AMI患者以尿激酶静脉溶栓治疗86例,根据发病时间将患者分为两组,6 h内组及6 h以上组,对比经溶栓治疗后其再通率及并发症发生率。结果 86例患者经静脉溶栓治疗再通61例,再通率为71.6%,发生出血3例,其中6 h内出血3例,均为轻度出血。发病4周内死亡5例,死亡率为5.8%。结论尿激酶静脉溶栓治疗安全、有效、价格便宜,是急性心肌梗死的一种有效治疗方法。
Objective To explore the effect and prognosis of the thrombolysis therapy by intravenous administering of urokinase for AMI.Methods 86 AMI patients who having received thrombolysis therapy by intravenous administering of urokinase were enrolled by retrospective analysis.They were assigned to two groups according to the time of morbidity,inner 6 hours group and above 6 hours group,comparing the recanalization rate and incidence rate of complication after thrombolysis therapy.Results 61 were recanalizaed in 86 patients who having received thrombolysis therapy,the recanalization rate was 71.6%.There were 3 pationts developed to hemorrhage,of which 3 in inner 6 hours group,all of them were hyporrhea.There were 3 pationts developed to death,death rate was 5.8%.Conclusion Thrombolysis therapy by intravenous administering of urokinase,which is safe,effective,price,is an effective treatment for acute myocardial infarction.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第20期2757-2758,共2页
Chongqing medicine
关键词
急性心肌梗死
尿激酶
静脉溶栓
再通
acute myocardial infarction
urokinase
thrombolysis therapy
recanalization
